Literature DB >> 7903702

Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion.

S L Berg1, K H Cowan, F M Balis, J S Fisherman, A M Denicoff, M Hillig, D G Poplack, J A O'Shaughnessy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7903702     DOI： 10.1093/jnci/86.2.143

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

1.  Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Authors:  Patrick Thompson; Heather E Wheeler; Shannon M Delaney; Rachel Lorier; Ulrich Broeckel; Meenakshi Devidas; Gregory H Reaman; Kathleen Scorsone; Lillian Sung; M Eileen Dolan; Stacey L Berg
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-14       Impact factor: 3.333

2.  A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Authors:  D Rischin; L K Webster; M J Millward; G C Toner; S Nawaratne; V Ganju; P Francis; J F Bishop
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.

Authors:  Romano Danesi; Federico Innocenti; Stefano Fogli; Alessandra Gennari; Editta Baldini; Antonello Di Paolo; Barbara Salvadori; Guido Bocci; Pier Franco Conte; Mario Del Tacca
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 4.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 5.  Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

Authors:  R Danesi; P F Conte; M Del Tacca
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of paclitaxel.

Authors:  D S Sonnichsen; M V Relling
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 7.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 8.  Current status of paclitaxel in the treatment of breast cancer.

Authors:  J A O'Shaughnessy; K H Cowan
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  A phase II trial of paclitaxel and epirubicin in advanced breast cancer.

Authors:  D Rischin; J Smith; M Millward; C Lewis; M Boyer; G Richardson; G Toner; H Gurney; J McKendrick
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.

Authors:  Zhenyou Zou; Ruyi Zou; Dan Zong; Yonghong Shi; Jinyao Chen; Jie Huang; Jiahui Zhu; Liguan Chen; Xiaoyan Bao; Yuan Liu; Weihao Liu; Wenhui Huang; Jingsang Hu; Zhi Chen; Xiaojie Lao; Chaoqun Chen; Xiaoli Huang; Yao Lu; Xueyin Ni; Daoquan Fang; Dengqiang Wu; Shuangshuang Lu; Mingzhu Jiang; Chenyang Qiu; Yuya Wu; Qisha Qiu; Yanyuan Dong; Yangyang Su; Chenmin Zhao; Zhihe Zhong; Jing Cai; Yong Liang
Journal:  J Cell Mol Med       Date:  2017-04-14       Impact factor: 5.310
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.